DocMeetings

The discovery of targetable oncogenic biomarkers in non-small cell lung cancer (NSCLC) has revolutionized its treatment. Current guidelines recommend fast and comprehensive biomarker screening for the selection of first-line targeted therapy or immunotherapy with or without chemotherapy. The number of actionable targets and the requirement for extensive molecular screening strategies are expected to increase in the coming years. This webinar will summarize how NSCLC biomarker testing can be expanded by RNA next-generation sequencing.

In this webinar you will learn:

• The nature of clinical NSCLC biomarker testing in Europe
• A clinician’s perspective on why the clinical environment should drive the focus of research testing
• How Invitae’s expanded lung in-house panel* is well positioned to drive successful research testing